Santen Pharmaceutical Co - Articles and news items

Vekacia meets primary and secondary endpoints in VKC trial

Industry news / 11 May 2016 / Victoria White, Digital Content Producer

Vekacia demonstrated efficacy and tolerability vs placebo in the treatment of active, severe vernal keratoconjunctivitis (VKC) in paediatric patients…

NICE says ‘yes’ to Santen’s dry eye disease treatment, ciclosporin

Industry news / 16 December 2015 / Victoria White

Ciclosporin (Ikervis) is a sterile, positively charged, oil-in water, unpreserved ophthalmic emulsion that contains ciclosporin (CsA)…

NICE recommends Ikervis in final draft guidance

Industry news / 4 November 2015 / Victoria White

Ikervis has been recommended for the treatment of keratitis in adults with dry eye disease who have not responded to tear substitutes…

NICE consults on dry eye treatment, ciclosporin, and asks for more information from the company

Industry news / 24 June 2015 /

NICE has today published preliminary recommendations on ciclosporin (Ikervis) for treating severe keratitis in adults with dry eye disease…


Santen Announces Approval of Ikervis for EU Marketing Authorisation

Industry news / 25 March 2015 / Victoria White

Santen Pharmaceutical has announced it received approval of the Marketing Authorisation Application (MAA) for Ikervis from the European Commission…


EMA accepts Santen’s Marketing Application filing for intravitreal sirolimus for the treatment of noninfectious uveitis of the posterior segment

Industry news / 2 March 2015 / Santen

Santen Pharmaceutical Co., Ltd. announced that the European Medicines Agency has accepted the company’s Marketing Authorization Application filing for the use of intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of noninfectious uveitis (NIU) of the posterior segment…


Santen announces appointment of Paolo Casati as General Manager of Santen Subsidiary in Italy

Industry news / 4 December 2014 / Santen

Following the launch of Santen in Italy in October 2014, Santen Italy s.r.l (Milano, Italy) (Santen) announces that Paolo Casati has been named General Manager of Santen Italy, effective November 21st, 2014…


Santen establishes subsidiary in United Kingdom

Industry news / 4 November 2014 / Santen Pharmaceutical Co

Santen Pharmaceutical Co., Ltd. announced the establishment of a wholly owned subsidiary in The United Kingdom (UK) to serve customers and patients in the UK and Ireland…


Santen announces positive outcome of the European Decentralized Procedure for approval of TAPTIQOM®

Industry news / 23 October 2014 / Santen

Santen GmbH. announced the positive outcome of the Decentralized Procedure (DCP) for TAPTIQOM® in Europe…


Santen launches its own Subsidiary in Italy

Industry news / 16 October 2014 / Santen Pharmaceutical Co

Santen Pharmaceutical Co., Ltd. announced its new wholly owned subsidiary in Italy…

Merck logo

Merck signs sale agreement with Santen for Merck’s ophthalmology products in Japan and key markets in Europe and Asia Pacific

Industry news / 13 May 2014 / Merck

Merck announced that it signed an agreement for Santen Pharmaceutical Co., Ltd. (Santen) to purchase Merck’s ophthalmology products…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...